IP Library › Granted Patent US 7,795,279
Granted Patent B2
US 7,795,279 · App. 11/550,077 · Granted Sep 14, 2010

Method of inhibiting FLT3 kinase

Assignee: Janssen Pharmaceutica NV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,279
App. No.
11/550,077
Granted
Sep 14, 2010
Kind
B2
Abstract

A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Claims (4)

1. A method for treating leukemia comprising administering to a subject in need thereof a compound:

or a pharmaceutically acceptable salt thereof.

2. A method of treating leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2007
From: BALLENTINE, SHELLY K.; BAUMANN, CHRISTIAN ANDREW; CHEN, JINSHENG; ILLIG, CARL R.; RUDOLPH, M. JONATHAN; WALL, MARK J.; WILSON, KENNETH; JOHNSON, DANA L.; TUMAN, ROBERT W.; MEEGALLA, SANATH K.
To: JANSSEN PHARMACEUTICA N.V.
Reel/Frame 018999/0320 →
Continuity (2)
Provisional Application 6072768700 · Oct 18, 2005
Related Publication 20070149572A1 · Jun 28, 2007